itestobart (TWP-101) / TheraWisdom Biopharma - LARVOL DELTA

Early safety and efficacy from a phase I clinical study of TWP-101, a novel CD137 agonist antibody, in patients with advanced melanoma and urothelial carcinoma. (ASCO 2023) - P1a/1b | "TWP-101 demonstrated a good safety profile without hepatotoxicity frequently observed with other studied CD137 antibodies. Both favorable tolerability and preliminary antitumor activity warrant further evaluation in pts with advanced melanoma and urothelial carcinoma. Clinical trial information: NCT04871334."

Clinical • IO biomarker • Metastases • P1 data • Anemia • Cardiovascular • Dyslipidemia • Heart Failure • Hematological Disorders • Hepatology • Hypertriglyceridemia • Immune Modulation • Leukopenia • Melanoma • Neutropenia • Oncology • Solid Tumor • Subarachnoid Hemorrhage • Urothelial Cancer